CANCER METRONOMIC THERAPY GASTROINTESTINAL CANCERS
|
|
- Gervais Richardson
- 5 years ago
- Views:
Transcription
1 AIOM Meeting Milan, 26 February 2016 CANCER METRONOMIC THERAPY GASTROINTESTINAL CANCERS Lisa Salvatore Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa
2 My Agenda The metronomic story: The Asian studies The European (Italian) studies Maintenance studies Open issues and possible future perspectives
3 A premise My focus will be on mcrc
4 The Asian Production
5 The Asian Production Study Lin, 2007 Ogata, 2007 Ogata, 2013 Phase Regimen FOLFOX >metrouft metrocpt DFUR metrocpt-11+s-1 Setting 5FU-resistant mcrc I-II line mcrc I line mcrc N Pts RR 35.7% 35.6% 48.9% PFS OS Tox G3/4 <5% 2% <10%
6 The Asian Production Study Lin, 2007 Ogata, 2007 Ogata, 2013 Phase Regimen FOLFOX >metrouft metrocpt DFUR metrocpt-11+s-1 Setting 5FU-resistant mcrc I-II line mcrc I line mcrc N Pts RR 35.7% 35.6% 48.9% PFS OS Tox G3/4 <5% 2% <10%
7 The Asian Production Study Lin, 2007 Ogata, 2007 Ogata, 2013 Phase Regimen FOLFOX >metrouft metrocpt DFUR metrocpt-11+s-1 Setting 5FU-resistant mcrc I-II line mcrc I line mcrc N Pts RR 35.7% 35.6% 48.9% PFS OS Tox G3/4 <5% 2% <10%
8 The Asian Production Study Lin, 2007 Ogata, 2007 Ogata, 2013 Phase Regimen FOLFOX >metrouft metrocpt DFUR metrocpt-11+s-1 Setting 5FU-resistant mcrc I-II line mcrc I line mcrc N Pts RR 35.7% 35.6% 48.9% PFS OS Tox G3/4 <5% 2% <10%
9 The Asian Production Study Lin, 2007 Ogata, 2007 Ogata, 2013 Phase Regimen FOLFOX >metrouft metrocpt DFUR metrocpt-11+s-1 Setting 5FU-resistant mcrc I-II line mcrc I line mcrc N Pts RR 35.7% 35.6% 48.9% PFS OS Tox G3/4 <5% 2% <10%
10 The European Production
11 The Italian Production Study Allegrini, 2008 Allegrini, 2012 Marmorino, 2013 Phase NA Regimen metrocpt-11 metrouft+ctx+cxb metro cape+ctx Setting advanced line mcrc advanced line GIC advanced line mcrc N Pts RR 0% 0% NA PFS OS Tox G3/4 0% 0% 0%
12 The Italian Production Study Allegrini, 2008 Allegrini, 2012 Marmorino, 2013 Phase NA Regimen metrocpt-11 metrouft+ctx+cxb metro cape+ctx Setting advanced line mcrc advanced line GIC advanced line mcrc N Pts RR 0% 0% NA PFS OS Tox G3/4 0% 0% 0%
13 The Italian Production Study Allegrini, 2008 Allegrini, 2012 Marmorino, 2013 Phase NA Regimen metrocpt-11 metrouft+ctx+cxb metro cape+ctx Setting advanced line mcrc advanced line GIC advanced line mcrc N Pts RR 0% 0% NA PFS OS Tox G3/4 0% 0% 0%
14 Asia vs Italy Study Lin, 2007 Allegrini, 2012 Marmorino, 2013 Phase Regimen FOLFOX >metrouft metrouft+ctx+cxb metro cape+ctx Setting 5FU-resistant mcrc advanced line GIC advanced line mcrc N Pts RR 35.7% 0% NA PFS OS Tox G3/4 <5% 0% 0%
15 Asia vs Italy Study Lin, 2007 Allegrini, 2012 Marmorino, 2013 Phase Regimen FOLFOX >metrouft metrouft+ctx+cxb metro cape+ctx Setting 5FU-resistant mcrc advanced line GIC advanced line mcrc N Pts RR 35.7% 0% NA PFS OS Tox G3/4 <5% 0% 0%
16 Asia vs Italy Study Lin, 2007 Allegrini, 2012 Marmorino, 2013 Phase Regimen FOLFOX >metrouft metrouft+ctx+cxb metro cape+ctx Setting 5FU-resistant mcrc advanced line GIC advanced line mcrc N Pts RR 35.7% 0% NA PFS OS Tox G3/4 <5% 0% 0%
17 Asia vs Italy: why such difference? Different ethnicity Different drugs and different schedules Different setting
18 Is metro really left out?
19 CAIRO-3: metro as maintenance tx Maintenance cape 625 mg/sqm/bid continuously Simkens et al, Lancet 2015
20 CAIRO-3: PFS Median PFS2 Observation 8.5 m Maintenance 11.7 m Stratified HR 0.67 [95%CI: ] p value < Median PFS1 Observation 4.1 m Maintenance 8.5 m Stratified HR 0.43 [95%CI: ] p value < Simkens et al, Lancet 2015
21 CAIRO-3: Tox G3/4 adverse events, Observation Maintenance p % patients N=279 N=278 Any G3/4 AEs < Hypertension HFS reaction 0 23 < Hyperbilirubinaemia < Adapted from Simkens et al, Lancet 2015
22 CAIRO-3: Tox G3/4 adverse events, Observation Maintenance p % patients N=279 N=278 Any G3/4 AEs < Hypertension HFS reaction 0 23 < Hyperbilirubinaemia < Adapted from Simkens et al, Lancet 2015
23 CAIRO-3: Tox G3/4 adverse events, Observation Maintenance p % patients N=279 N=278 Any G3/4 AEs < Hypertension HFS reaction 0 23 < Hyperbilirubinaemia < Adapted from Simkens et al, Lancet 2015
24 Nordic ACT2: metro as maintenance tx N=71 N=67 Maintenance cape 500 mg twice daily continuously Hagman et al, Ann Oncol 2016
25 Nordic ACT2: metro cape as maintenance tx KRAS mut Bev (N=34) Metro Cape (N=33) 3mos PFR PFS OS 75% 66.7% p= HR=1.19; p= HR=1.57; p=0.128 G3/4 AEs 20.6% 15.2% Adapted from Hagman et al, Ann Oncol 2016
26 Can maintenance metro cape have a future? Hagman et al, Ann Oncol 2016
27 A Made in Italy study was born: the MOMA trial Started on May partecipating centers Sponsored by 3
28 MOMA Study: maintenance metro CT + Bev Randomized phase II study 1st line Unresectable mcrc pts R 1:1 N=232 Arm A Arm B FOLFOXIRI + bevacizumab x 8 cycles FOLFOXIRI + bevacizumab x 8 cycles Bevacizumab until PD Bevacizumab + metro CT* until PD Primary endpoint: PFS *Cape 500 mg/tid continuously CTX 50 mg/die continuously
29 Open Issues Defining the optimal drug Defining the optimal dose Defining the optimal schedule Defining the optimal combination Better understanding the metro mechanism of action
30 Possible future perspectives Metro + Immunotp Metro + Bev Metro + CT Pasquier et al, Nature Rev 2010
31 Take home messages No role of metro in advanced line mcrc Maybe a role of metro as maintenance tx (waiting for MOMA) Open issues (drug, dose, schedule, combination) Several targets and several actions: antiangiogenic, cytotoxic and immunotp
32
Colon Cancer ASCO Poster Review
Rome, February 11 th 2017 AIOM POST ASCO GI Review Colon Cancer ASCO Poster Review Lisa Salvatore UOC Oncologia Policlinico GB Rossi Azienda Ospedaliero Universitaria Integrata di Verona Me Before Me After
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationPharmacokinetics, pharmacodynamics and pharmacogenetics of metronomic chemotherapy
Divisione di Farmacologia Dipartimento di Medicina Clinica and Sperimentale Università di Pisa U.O. Farmacologia Clinica Azienda Ospedaliero Universitaria Pisana Pharmacokinetics, pharmacodynamics and
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationReview of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups. Chemotherapy and targeted agents in 1st line
ESMO Preceptorship Programme Colorectal Cancer Valencia, 18th May 2018 Review of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups Chemotherapy and targeted agents
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationAnnals of Oncology Advance Access published January 18, 2015
Annals of Oncology Advance Access published January 18, 2015 1 Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationKonzepte bei der Therapie des metastasierten kolorektalen Karzinoms
21. Ärzte Fortbildungskurs in Klinischer Onkologie 24.-26. Februar 2011 Kantonspital St. Gallen / Schweiz Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms Claus-Henning Köhne Klinik
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationRECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER
RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationNuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos?
Nuevos Agentes en el Manejo de Cáncer Colorectal: Dónde Incorporalos? Prof. Dr. Paulo M. Hoff Instituto do Câncer do Estado de São Paulo - ICESP Faculdade de Medicina Universidade de São Paulo (USP) Conflicts
More informationTraitement de 2ème ligne du cancer colorectal métastatique : nouvelles données cliniques en 2018
GR DIG 2017 Traitement de 2ème ligne du cancer colorectal métastatique : nouvelles données cliniques en 2018 9 décembre 2017 Benoist Chibaudel Oncologie Médicale Institut Hospitalier Franco-Britannique,
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationWhat s New? Dr. Barbara Melosky
Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment
More informationHot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon
Convegno Nazionale AIOM Giovani 2018 News in Oncology Hot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon Daniele Rossini U.O. di Oncologia Medica
More informationMANAGEMENT OF ADVANCED COLORECTAL CANCER
MANAGEMENT OF ADVANCED COLORECTAL CANCER Alberto Sobrero IRCCS San Martino IST Genoa Italy Disclosures : Pfizer, Roche, Merck, Amgen, Celgene, Bayer, Sanofi, Nordic, Takeda,BMS, Syrtex, Servier outline
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationGI SLIDE DECK. Selected abstracts from: 31 May 4 Jun 2013 Chicago, USA ASCO Annual Meeting. 27 Sep 1 Oct 2013 Amsterdam, Netherlands ESMO-ECCO
GI SLIDE DECK 31 May 4 Jun 2013 Chicago, USA ASCO Annual Meeting 2013 Selected abstracts from: 3 Jul 6 Jul 2013 Barcelona, Spain WCGIC 27 Sep 1 Oct 2013 Amsterdam, Netherlands ESMO-ECCO Supported by Eli
More informationPanel Two: Evidence for Use of Maintenance Therapy
Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationThe role of Maintenance treatment Appropriate endpoints according to ESMO consensus
ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationUnresectable or boarderline resectable (Groupp 1) chemotherpy +/- targeted agents
ESMO Preceptorship Program 27.-28. March Singapore Unresectable or boarderline resectable (Groupp 1) chemotherpy +/- targeted agents Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationColorectal Cancer: Critical review
AIOM POST-ASCO 2018 Updates and Review from Chicago Milano, June 15-16, 2018 Colorectal Cancer: Critical review Alfredo Falcone, MD Department of Oncology and Translational Medicine University of Pisa
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Rectal Cancer Pathway V8, April 2015 Diagnostic Workup: Bethesda Criteria: Pathology Review All patients H&P All patients Biopsy All patients Colonoscopy All patients CEA All Patients Chest/Abdominal/Pelvic
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationSystemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
More informationSUMMARY OF THE SIRFLOX RESULTS
SUMMARY OF THE SIRFLOX RESULTS The SIRFLOX study results on the combination of SIR-Spheres Y-90 resin microspheres with first-line chemotherapy were published in Journal of Oncology in early 2016. 1 There
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationEndpoints in Gynecologic Cancer Clinical Trials
Endpoints in Gynecologic Cancer Clinical Trials Keiichi Fujiwara Saitama Medical University International Medical Center GOTIC AGENDA Definition of Endpoint Variation of Endpoint Primary vs Secondary Direct
More informationUniversità degli Studi di Pisa Facoltà di Medicina e Chirurgia Scuola di Specializzazione in Oncologia
Università degli Studi di Pisa Facoltà di Medicina e Chirurgia Scuola di Specializzazione in Oncologia Tesi di Specializzazione EZH2 polymorphisms and outcome of metastatic colorectal cancer patients Candidato:
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationLa strategia terapeutica del carcinoma del colon metastatico
Dalla Capecitabina al TAS-102 Milano, 29 settembre 2016 La strategia terapeutica del carcinoma del colon metastatico Gianluca Masi U.O. di Oncologia Medica Universitaria Azienda Ospedaliero-Universitaria
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationKolorektalni karcinom- novosti u liječenju. PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić
Kolorektalni karcinom- novosti u liječenju PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić Kolorektalni karcinomnovosti u liječenju PANEL : Maja Banjin, Janja Ocvirk, Borislav
More informationManagement Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study
Management Of Patients With Metastatic Colorectal Cancer in Lebanese Hospitals and Associated Direct Cost: A Multicenter Cohort Study Henaine AM; Chahine G; Massoud M; Salameh P; Awada S; Lahoud N; El
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationReDOS Trial Background
Regorafenib Dose Optimization Study (ReDos) A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mcrc) Abstract
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationTHE BEST OF ESMO 2016
THE BEST OF ESMO 2016 Colorectal cancer Pr Julien TAIEB, Sorbonne Paris Cité and Paris Descartes University Georges Pompidou European Hospital Paris, FRANCE esmo.org DISCLOSURES JT has received research
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationRandomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
DOI: 10.1093/jnci/djq456 Advance Access publication on December 1, 2010 The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationFighting a Smarter War On Colon Cancer:
Fighting a Smarter War On Colon Cancer: Value as a new endpoint? John L. Marshall, MD Tel: (202) 444-0275 Fax: (202) 444-1229 http://lombardi.georgetown.edu/gi Stakeholder Motivation Stakeholders FDA CMS/Payers
More informationGRUPPO ONCOLOGICO NORD-OVEST EUDRACT Protocol Vers. 3.0 November 25 th,
G.O.N.O. GRUPPO ONCOLOGICO NORD-OVEST INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE RAS AND BRAF WILD-TYPE METASTATIC COLORECTAL
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationWhat to do after 1 st line failure?
ESMO Preceptorship Programme Colorectal Cancer Singapore 20-22 nd 2016 JY Douillard MD PhD ESMO CMO What to do after 1 st line failure? mcrc: How to maximize survival? Improving 1st line therapy efficacy
More information